Financial Performance - Net profit attributable to shareholders reached CNY 1,186,355,315.52, a significant increase of 2,601.42% year-on-year[14]. - Operating revenue surged to CNY 2,235,856,344.48, reflecting a year-on-year growth of 1,925.91%[14]. - Basic earnings per share reached CNY 9.89, up 2,572.97% from CNY 0.37 in the previous year[14]. - The net profit after deducting non-recurring gains and losses was CNY 1,184,005,687.52, an increase of 2,660.48% year-on-year[14]. - The total net profit for the quarter included non-recurring gains of CNY 2,349,628.00[17]. - Operating profit for Q1 2021 was ¥1,377,376,219.57, up from ¥53,542,455.32 in Q1 2020, reflecting a growth of 2,570.5%[53]. - Net profit attributable to shareholders for Q1 2021 was ¥1,186,355,315.52, compared to ¥43,916,037.42 in Q1 2020, marking an increase of 2,694.5%[55]. - The company achieved a total comprehensive income of ¥1,188,111,525.52 in Q1 2021, significantly higher than ¥45,990,149.80 in Q1 2020, an increase of 2,480.5%[55]. Asset and Equity Growth - Total assets increased by 38.80% to CNY 4,959,720,348.96 compared to the end of the previous year[14]. - The company reported a significant increase in net assets attributable to shareholders, which rose by 48.58% to CNY 3,634,420,579.62 compared to the end of the previous year[14]. - The total equity attributable to the parent company increased to ¥3,634,420,579.62, a rise of 48.58% compared to ¥2,446,042,711.91 in the same period last year, driven by significant operational performance growth[28]. - The company's equity attributable to shareholders rose to approximately ¥3.63 billion, compared to ¥2.45 billion, indicating a growth of 48.3% year-over-year[48]. Cash Flow and Liquidity - Net cash flow from operating activities increased by 792.53% to CNY 1,277,675,312.02 compared to the same period last year[14]. - Cash received from sales of goods and services was ¥2,183,953,382.26, a 736.60% increase from ¥261,052,173.49[28]. - The net increase in cash and cash equivalents was CNY 992.42 million, compared to CNY 86.61 million in the same quarter last year[67]. - The ending balance of cash and cash equivalents was CNY 2.79 billion, up from CNY 171.96 million in the previous year[67]. Research and Development - Research and development expenses accounted for 1.04% of operating revenue, a decrease of 6.09 percentage points year-on-year[14]. - Research and development expenses increased to ¥23,299,512.68, a 195.99% rise from ¥7,871,766.61, reflecting enhanced investment in new product development[28]. - Research and development expenses in Q1 2021 totaled ¥23,299,512.68, which is an increase of 195.5% from ¥7,871,766.61 in Q1 2020[53]. Inventory and Liabilities - Inventory rose by 62.47% to ¥619,944,913.78 from ¥381,578,076.46, reflecting a substantial increase in orders[25]. - Current liabilities totaled approximately ¥1.31 billion, compared to ¥1.11 billion, reflecting an increase of 17.8% year-over-year[46]. - Total liabilities increased to approximately ¥1.32 billion, up from ¥1.12 billion, representing a growth of 18.7% year-over-year[48]. - Accounts payable rose to approximately ¥623.57 million, up from ¥371.97 million, marking a significant increase of 77.5% year-over-year[42]. Tax and Other Financial Metrics - Tax payable increased by 48.75% to ¥521,359,318.36 from ¥350,489,621.78, mainly due to an increase in income tax payable[25]. - The company reported a tax expense of ¥191,285,405.64 for Q1 2021, compared to ¥7,736,910.32 in Q1 2020, indicating a rise of 2,373.5%[53]. - Other comprehensive income after tax for Q1 2021 was ¥2,022,552.19, compared to ¥327,527.75 in Q1 2020, reflecting a growth of 517.5%[55]. Shareholder Information - The company has a total of 12,837 shareholders, with the top ten shareholders holding significant stakes[21].

2020 年第三季度报告 公司代码：688298 公司简称：东方生物 浙江东方基因生物制品股份有限公司 2020 年第三季度报告 1 / 21 2020 年第三季度报告 一、 i Í 三、 四、 目 录 | --- | --- | |--------------|-------| | | | | 重要提示 | | | 公司基本情况 | | | 重要事项 | | | 附录 | | 2 / 21 2020 年第三季度报告 单位：元 币种：人民币 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人方效良、主管会计工作负责人俞锦洪及会计机构负责人（会计主管人员）金炜彦 保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 | --- | --- | --- | --- | |-------------------------------------------- ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2020, with total revenue reaching 500 million RMB, representing a 25% year-over-year growth[2]. - The company's revenue for the first half of 2020 reached ¥828,150,045.54, representing a 388.05% increase compared to ¥169,686,760.35 in the same period last year[28]. - Net profit attributable to shareholders of the listed company was ¥523,946,799.85, a significant increase of 1,477.45% from ¥33,214,692.81 in the previous year[28]. - The net profit after deducting non-recurring gains and losses was ¥517,381,502.39, up 1,647.20% from ¥29,612,071.93 year-on-year[28]. - The net cash flow from operating activities was ¥367,308,421.20, a dramatic increase of 12,509.96% compared to ¥2,912,842.65 in the same period last year[28]. - The company's basic and diluted earnings per share for the reporting period (January to June) reached 4.37 CNY, a significant increase of 1,081.08% compared to the same period last year[29]. - Operating revenue for the reporting period grew by 388.05%, mainly driven by the sales of COVID-19 testing reagents[33]. - The company reported a total revenue of 13,324.44 million RMB, with a gross profit of 2,670.12 million RMB, indicating a significant increase in performance compared to previous periods[73]. Market Outlook and Growth Strategy - The company has provided a positive outlook for the second half of 2020, projecting a revenue growth of 20% to 30% based on current market trends and demand[2]. - User data indicates a growing customer base, with an increase of 15% in active users compared to the previous year, totaling 1.2 million active users[2]. - The company is expanding its market presence, targeting an increase in distribution channels by 40% in the next six months[2]. - Strategic acquisitions are planned, with a focus on acquiring two smaller biotech firms to enhance R&D capabilities and product offerings[2]. - The company has identified potential risks, including regulatory changes and market competition, which could impact future performance[5]. Research and Development - The company has developed three new COVID-19 testing reagents, which significantly contributed to the growth in operating performance during the reporting period[43]. - The company has established a global R&D team and has set up subsidiaries in Canada and Qingdao to focus on the development of antigens and antibodies[45]. - The company has completed the R&D of several molecular diagnostic products, with some already industrialized, and is in the final testing stage for its liquid biochip detection instrument[43]. - The company is strategically investing in the development of molecular diagnostics and liquid biopsy technologies, aiming for gradual industrialization[56]. - The company has established a strong R&D foundation with numerous patents and technologies, covering applications in infectious disease testing, drug testing, and tumor detection[59]. - The company has developed multiple COVID-19 related testing kits, including the COVID-19 IgG/IgM Rapid Test Cassette and SARS-CoV-2 Detection Kit, with various certifications obtained[62]. - The company is currently working on 14 research projects, with total expected investment of ¥1,100 million across all projects[67]. Product Development and Certifications - The company has developed core technologies in POCT instant diagnostic reagents, including various advanced techniques such as high-concentration gold preparation and fluorescence immunoassay technology[56]. - The company achieved a total of 442 medical device registrations and certifications by the end of the reporting period, with 410 new registrations added during the period[60]. - The company received 259 CE certifications in the EU, an increase of 25 from the previous count[60]. - The company obtained 35 FDA 510(k) approvals in the US, with 1 new approval during the reporting period[60]. - The company registered 8 Class I medical devices in China, with an increase of 1 during the reporting period[60]. - The company registered 54 Class II medical devices in China, with an increase of 3 during the reporting period[60]. - The company registered 10 Class III medical devices in China, with an increase of 1 during the reporting period[60]. Financial Position and Assets - The net assets attributable to shareholders of the listed company at the end of the reporting period were ¥1,302,070,553.80, reflecting a 417.25% increase from ¥251,728,329.24 at the end of the previous year[28]. - Total assets amounted to ¥1,623,708,392.10, which is a 349.14% increase compared to ¥361,511,480.07 at the end of the previous year[28]. - The company's cash and cash equivalents increased by 366.47% to 398,535,875.27 RMB, primarily due to increased fundraising and collection of receivables[77]. - The company's accounts receivable rose by 202.27% to 250,948,011.90 RMB, driven by growth in operating income[77]. - The company's inventory increased by 192.42% to 227,981,174.86 RMB, reflecting a significant rise in production materials and finished goods due to increased orders[77]. Corporate Governance and Compliance - The company has committed to a consistent action agreement, prohibiting unilateral actions that could affect control changes for a period of 36 months post-IPO[119]. - Shareholders are restricted from transferring or managing shares for 36 months post-IPO, with automatic extensions if stock prices fall below the IPO price for 20 consecutive trading days[119]. - The company has outlined specific commitments regarding share lock-up periods, ensuring stability in shareholding during the initial public offering phase[119]. - The company has made commitments to avoid competition with its controlling shareholders and core technical personnel, as detailed in the prospectus[126]. - The company has provided assurances regarding employee compensation levels, as mentioned in the prospectus[126]. - The company has maintained a focus on compliance with corporate governance and information disclosure regulations following the warning received[132]. Risks and Challenges - The company faced risks from U.S.-China trade tensions, which could impact product sales and business expansion[96]. - Future sales performance is uncertain due to intensified competition in the COVID-19 testing market and potential regulatory changes[100]. - The company has reported no significant litigation or arbitration matters during the reporting period[129].

Financial Performance - In 2019, the company's operating income reached CNY 36,737.68 million, representing a 28.50% increase compared to 2018[27]. - The net profit attributable to shareholders of the listed company was CNY 8,210.52 million, a 25.60% increase from the previous year[27]. - The net profit after deducting non-recurring gains and losses was CNY 7,601.66 million, up 21.43% year-on-year[27]. - The net cash flow from operating activities was CNY 5,421.21 million, reflecting a 22.30% increase compared to 2018[27]. - As of the end of 2019, the net assets attributable to shareholders of the listed company were CNY 25,172.83 million, a 25.22% increase from the end of 2018[27]. - The total assets at the end of 2019 amounted to CNY 36,151.15 million, showing a 7.07% increase from the previous year[27]. - Basic earnings per share (CNY/share) increased to 0.91 from 0.73, a growth of 24.66%[30]. - Diluted earnings per share (CNY/share) also rose to 0.91 from 0.73, reflecting a 24.66% increase[30]. - The company achieved a main business revenue of 367 million yuan in 2019, representing a growth of 28.50% compared to the previous year[125]. - The net profit attributable to shareholders reached 82.1 million yuan, an increase of 25.60% year-over-year[125]. - Total assets at the end of 2019 were 361 million yuan, reflecting a growth of 7.07% since the beginning of the year[125]. - Net assets increased to 254 million yuan, a growth of 22.16% from the start of the year[125]. - The company maintained a debt-to-asset ratio of 29.70%, indicating a stable financial position[125]. - The return on equity was 37.13%, demonstrating effective value enhancement for shareholders[125]. Research and Development - R&D investment as a percentage of operating revenue increased to 8.64%, up by 2.12 percentage points from the previous year[30]. - The total R&D investment for the period was ¥31,755,944.68, which accounts for 8.64% of the company's operating revenue[92]. - The company has a total of 131 R&D personnel, representing 12.57% of the total workforce[92]. - The company has developed over 400 domestic and international product certifications, making it one of the Chinese in vitro diagnostic companies with the most international product certifications[72]. - The company emphasizes continuous R&D investment and expertise acquisition, resulting in a robust patent portfolio and advanced diagnostic product offerings[72]. - The company added 38 new patents in 2019, including 29 domestic and 9 foreign patents, enhancing its competitive edge in the industry[85]. - The company has established six technical platforms, including immunodiagnostic, biochemical diagnostic, biological raw materials, molecular diagnostic, liquid biopsy chip, and in vitro diagnostic instrument platforms[73]. - The company is focused on expanding its product lines and enhancing its technological capabilities to meet the growing market demand[52]. - The company has established a strong patent portfolio to support its market expansion and product development strategies[87]. - The company is actively pursuing international patent protection, with several patents granted in Europe and the United States[89]. Market Expansion and Strategy - The company aims to enhance its market presence through strategic partnerships and potential acquisitions in the healthcare sector[18]. - The company is focused on expanding its product offerings in the in vitro diagnostic market, including biochemical, immunological, and molecular diagnostic reagents[18]. - The company has established a strong international presence, with approximately 95% of its sales coming from overseas markets, serving over 100 countries[56]. - The company has developed multiple proprietary brands, including HEALGEN, DIAGNOSTAR, and ORIENT GENE, enhancing its brand recognition in international markets[47]. - The company is exploring potential mergers and acquisitions to further strengthen its market position and product range[183]. - The company is focusing on expanding its market presence in North America with FDA certifications for several products[182]. - The company is committed to leveraging its existing certifications to penetrate new markets and increase revenue streams[176]. - The company has maintained a strong pipeline of new product registrations, indicating ongoing investment in research and development[176]. Product Development and Innovation - The company has developed various new detection devices, including a rapid detection device for fluids and a multi-parameter biological detection instrument[87][90]. - The company has launched new drug testing kits, including for substances like methcathinone and fentanyl, becoming one of the richest product lines in domestic drug testing[77]. - The company has developed several health screening test kits for women of childbearing age and pregnant women, with a focus on high-end markets, showing a competitive advantage in speed and sensitivity compared to similar products[20]. - The company is developing blood glucose and lipid detection reagents, with a stable market share due to the increasing number of individuals with elevated levels[24]. - The company has completed the development of 17 nucleic acid test reagents for tumors and infectious diseases, successfully registered and launched in the market, indicating broad application prospects[30]. - The company has developed a unique sample processing technology for molecular diagnostics, significantly reducing processing time while ensuring RNA and DNA purification[111]. - The company has completed the development of a liquid biochip detection instrument, which is expected to fill a technological gap in China and replace imported products[112]. - The company is working on a new type of tranquilizer testing reagent, with an investment of CNY 70 million and CNY 12.78 million spent, indicating a market need for sensitive detection methods[99]. Regulatory Compliance and Certifications - The company is committed to maintaining compliance with international regulatory standards, including FDA and CE certifications for its products[19]. - The company has passed rigorous quality control certifications, including ISO13485:2016 and FDA inspections, ensuring high standards in production and quality management[120]. - The company received 64 new EU CE certifications in 2019, totaling 234 certifications, and 1 new FDA (510K) certification, totaling 34 certifications[85]. - The company has registered a total of 7 new Class I medical device filings, increasing from 3 at the beginning of the period, representing a 133.33% growth[176]. - The company maintained 51 Class II medical device registrations with no new additions or expirations, indicating stability in this category[176]. Operational Risks and Challenges - The company has detailed various operational risks and corresponding mitigation measures in the report, emphasizing the importance of risk management in its operations[5]. - The company faces risks related to new product development, including potential delays and high costs, which could impact its market competitiveness[129]. - The company faced risks related to strict regulatory requirements in the medical device industry, which could impact future operations if compliance is not maintained[142].

Financial Performance - Net profit attributable to shareholders increased by 262.52% to CNY 43,916,037.42 year-on-year[10] - Operating income rose by 39.21% to CNY 110,363,284.73 compared to the same period last year[10] - Basic earnings per share increased by 184.62% to CNY 0.37 compared to the same period last year[10] - The company reported a net profit excluding non-recurring gains and losses of CNY 42,891,371.26, up 302.49% year-on-year[10] - Net profit surged by 301.48% to RMB 45,662,622.05 from RMB 11,373,533.86, attributed to increased sales of COVID-19 testing products[21] - Total operating revenue for Q1 2020 was $110.36 million, a 39.2% increase from $79.28 million in Q1 2019[44] - Operating profit for Q1 2020 was $53.54 million, significantly up from $12.05 million in Q1 2019, marking a growth of 344.5%[44] - Net profit for Q1 2020 reached $45.66 million, compared to $11.37 million in Q1 2019, an increase of 302.5%[46] - The total profit for Q1 2020 was $53.40 million, compared to $13.82 million in Q1 2019, an increase of 286.5%[46] - The company achieved a total comprehensive income of $45.99 million in Q1 2020, significantly higher than $10.83 million in Q1 2019, marking a growth of 325.5%[46] Assets and Liabilities - Total assets increased by 205.92% to CNY 1,105,937,924.13 compared to the end of the previous year[10] - The company's total equity attributable to shareholders increased by 236.39% to RMB 846,789,794.67 from RMB 251,728,329.24, reflecting the successful capital raise and profit growth[21] - Current liabilities rose to ¥239,172,948.82 compared to ¥91,516,969.01, indicating increased short-term financial obligations[32] - Total liabilities amounted to ¥255,003,326.54, up from ¥107,384,932.56, reflecting higher financial leverage[34] - Shareholders' equity increased to ¥850,934,597.59 from ¥254,126,547.51, demonstrating strong retained earnings growth[34] Cash Flow - Net cash flow from operating activities surged by 5,837.70% to CNY 143,151,308.57 year-to-date[10] - Cash inflow from operating activities totaled CNY 269,910,429.58, significantly higher than CNY 77,849,055.84 in the same quarter last year[54] - Cash outflow from investing activities was CNY 676,953,504.74, leading to a net cash flow from investing activities of -CNY 616,935,360.45[54] - Cash inflow from financing activities was CNY 578,898,359.62, while cash outflow was CNY 21,065,465.79, resulting in a net cash flow from financing activities of CNY 557,832,893.83[56] - The net increase in cash and cash equivalents was CNY 86,610,902.35, compared to a decrease of CNY 8,584,754.93 in the previous year[56] Shareholder Information - The total number of shareholders at the end of the reporting period was 13,623[16] - The top shareholder, Anji Fulanglai Import and Export Trade Co., Ltd., held 19.50% of the shares[16] Research and Development - The proportion of R&D investment to operating income decreased by 1.56 percentage points to 7.13%[10] - Research and development expenses increased to $7.87 million in Q1 2020 from $6.89 million in Q1 2019, a rise of 14.3%[44] Market Strategy - The company plans to continue expanding its market presence and product offerings, particularly in the field of COVID-19 related products[21] Other Financial Metrics - The weighted average return on equity increased by 0.99 percentage points to 6.85%[10] - The company reported a significant increase in inventory by 36.91% to RMB 106,740,136.03 from RMB 77,963,649.97, driven by increased orders[19] - The company reported a financial income of $3.12 million in Q1 2020, compared to a financial expense of $3.51 million in Q1 2019, indicating a turnaround[44] - Other comprehensive income after tax for Q1 2020 was $327,527.75, contrasting with a loss of $545,982.40 in Q1 2019[46]